Bcel stock forecast.
According to the issued ratings of 9 analysts in the last year, the consensus rating for Hudbay Minerals stock is Moderate Buy based on the current 2 hold ratings and 7 buy ratings for HBM. The average twelve-month price prediction for Hudbay Minerals is C$9.18 with a high price target of C$10.50 and a low price target of C$8.00.
Shares of Atreca, Inc. (. BCEL Quick Quote. BCEL - Free Report) have been struggling lately and have lost 20% over the past week. However, a hammer chart pattern was formed in its last trading ...Analyst projections state that BCEL is forecast to be at a low of $1.00 and a high of $9.00. In order for the stock price to hit the forecast high, the stock would need to plunge -3361.54% from its current level, while the stock would need to crash -284.62% from its current level to reach the projected low. Atreca Inc (BCEL) estimates and forecastsOver the last year, the company’s stock hit its highest at $2.05 on 01/31/23, while the lowest price during the same time frame was $0.21, recorded on 10/09/23. 52-week price history of BCEL Stock. The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential.According to the issued ratings of 5 analysts in the last year, the consensus rating for Atreca stock is Hold based on the current 4 hold ratings and 1 buy rating for …
According to . 3 Wall Street analysts that have issued a 1 year BCEL price target, the average BCEL price target is $9.00, with the highest BCEL stock price forecast at $25.00 and the lowest BCEL stock price forecast at $1.00.
Atreca, Inc. (BCEL.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Atreca, Inc. | Nasdaq: BCEL | Nasdaq
The 360 Finance, Inc. stock price fell by -2.78% on the last day (Wednesday, 22nd Nov 2023) from $16.53 to $16.07. During the last trading day the stock fluctuated 4.68% from a day low at $15.81 to a day high of $16.55. The price has risen in 6 of the last 10 days and is up by 4.15% over the past 2 weeks.Atreca stock forecast report. View BCEL price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data.FIXX Stock 12 Months Forecast. Based on 1 Wall Street analysts offering 12 month price targets for Homology Medicines in the last 3 months. The average price target is $1.50 with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 167.81% change from the last price of $0.56.Stock Price Forecast. The 17 analysts offering 12-month price forecasts for BCE Inc have a median target of 41.19, with a high estimate of 45.64 and a low estimate of 39.16. The median estimate ...Apr 6, 2023 · Zacks Equity Research. April 6, 2023 at 9:55 AM · 3 min read. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer chart pattern was ...
According to the issued ratings of 5 analysts in the last year, the consensus rating for Atreca stock is Hold based on the current 4 hold ratings and 1 buy rating for …
Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...
Atreca, Inc.’s BCEL shares plunged about 37% on Aug 11, 2023, after the company reported structural changes in its business in the second-quarter earnings release, which failed to meet investors ...Dec 1, 2023 · Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. See Atreca, Inc. (BCEL) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.231.40. -1.20%. 108.31K. Find the latest Atreca Inc (BCEL) stock forecast, 12-month price target, predictions and analyst recommendations.VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.Stock Price Forecast. The 18 analysts offering 12-month price forecasts for Nu Holdings Ltd have a median target of 9.75, with a high estimate of 16.00 and a low estimate of 6.00. The median ...
Atreca Inc Cl A (BCEL) Company Description. Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism ... Find the latest Patterson-UTI Energy, Inc. (PTEN) stock quote, history, news and other vital information to help you with your stock trading and investing.According to . 3 Wall Street analysts that have issued a 1 year BCEL price target, the average BCEL price target is $9.00, with the highest BCEL stock price forecast at $25.00 and the lowest BCEL stock price forecast at $1.00.Stock Price Forecast. The 17 analysts offering 12-month price forecasts for BCE Inc have a median target of 41.19, with a high estimate of 45.64 and a low estimate of 39.16. The median estimate ... According to the National Snow & Ice Data Center, blizzard prediction relies on modeling weather systems, as well as predicting temperatures. The heavy snowfall that blizzards create can be hard to predict in advance.As the old saying goes, “Forewarned is forearmed.” This sentiment holds true when it comes to weather forecasting as well. One of the primary advantages of a 30-day extended weather forecast is the ability to plan ahead with confidence.Average. $3.25. Current Price. $0.21. Options. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...
VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.
Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...BCEL Stock Predictions, Articles, and Atreca Inc Cl A News From InvestorPlace From the Web 3 Penny Stocks to Catapult You Into the Millionaires’ Club By Omor Ibne Ehsan Jul 13, 2023 ...1 analysts 33.33% Hold 2 analysts 66.67% Sell 0 analysts 0% Strong Sell 0 analysts 0% Be the first to know when Wall Street analysts revise their BCEL stock forecasts and price …Last reporting date. November 13, 2023. EPS forecast (this quarter) -$68.00. Annual revenue (last year) $1.1B. Annual profit (last year) -$415.6M. Net profit margin.The rating of the stock has changed to hold according to some analysts. It's at an all time low, buy folks thanks me later. Recently BCEL has reached an all time low and a data suggests that is will rise back up. According to Fintel.IO Blackrock has bought a staggering 350k shares. The rating of the stock has changed to hold according to some ...11.30% of Atreca stock is owned by insiders. Which Atreca insiders have been selling company stock? The following insiders have sold BCEL shares in the last 24 months: Bros. Advisors Lp Baker ($109,895.60), John A Orwin ($37,216.24), Phillips Courtney ($15,321.16), and Tito Serafini ($199,122.53).April 06, 2023 — 09:55 am EDT. Written by Zacks Equity Research for Zacks ->. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer ...BANQUE POUR LE COMMERCE EXTERIEUR LAO PUBLIC. Date: Previous day: Opening : Last: Change: Change (%) High: Low: Trading Volume (shr) Trading Value (LAK)Stock Price Forecast. The 17 analysts offering 12-month price forecasts for BCE Inc have a median target of 41.19, with a high estimate of 45.64 and a low estimate of 39.16. The median estimate ...
Apr 6, 2023 · Zacks Equity Research. April 6, 2023 at 9:55 AM · 3 min read. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer chart pattern was ...
BCEL reported Q4'22 and full year earnings on March 29. Cash, cash equivalents and investments were $70.5M at the end of 2022. R&D expenses were $66.8M for 2022 and G&A expenses were $31.5M for ...
See Atreca, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... The 4 analysts offering 1 year …Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response.Find real-time BCE - BCE Inc stock quotes, company profile, news and forecasts from CNN Business.Find real-time NU - Nu Holdings Ltd stock quotes, company profile, news and forecasts from CNN Business.See Atreca, Inc. (BCEL) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Atreca Inc (NASDAQ:BCEL)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.24. At the close of trading, the stock’s price was $0.21. The BCEL share’s 52-week high remains $2.05, putting it -876.19% down since that peak but still an impressive 9.52% since price per share fell to its 52 ...Apr 6, 2023 · Zacks Equity Research. April 6, 2023 at 9:55 AM · 3 min read. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer chart pattern was ... Their VKTX share price targets range from $19.00 to $37.00. On average, they predict the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price. View analysts price targets for VKTX or view top-rated stocks among Wall Street analysts.April 06, 2023 — 09:55 am EDT. Written by Zacks Equity Research for Zacks ->. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer ...
Atreca, Inc. (BCEL) stock forecast and price target. Find the latest Atreca, Inc. BCEL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.Stock Price Forecast. The 8 analysts offering 12-month price forecasts for EyePoint Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 55.00 and a low estimate of 20.00 ...BCEL reported Q4'22 and full year earnings on March 29. Cash, cash equivalents and investments were $70.5M at the end of 2022. R&D expenses were $66.8M for 2022 and G&A expenses were $31.5M for ...Instagram:https://instagram. single parent home loanmost trusted forex trading platformbest bot cryptoameritrade day trading HOOK Stock 12 Months Forecast. $6.83. (1382.20% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Hookipa Pharma in the last 3 months. The average price target is $6.83 with a high forecast of $7.00 and a low forecast of $6.50. The average price target represents a 1382.20% change from the last price of $0.46. silver dollar value 1921forex.com maximum leverage Find real-time CBAY - CymaBay Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. pomerantz llp 1 analysts 33.33% Hold 2 analysts 66.67% Sell 0 analysts 0% Strong Sell 0 analysts 0% Be the first to know when Wall Street analysts revise their BCEL stock forecasts and price …Earnings announcement* for BCEL: Our vendor, Zacks Investment Research, hasn't provided us with the upcoming earnings report date. BCEL has a "high" Earnings Quality Ranking (EQR) for the 5th ...The Atreca stock forecast for tomorrow is $ 0.213730, which would represent a -4.16% loss compared to the current price. In the next week, the price of BCEL is expected to decrease by -24.67% and hit $ 0.167988. As far as the long-term Atreca stock forecast is concerned, here’s what our ...